APOA1 and metabolic dysfunction-associated steatotic liver disease: The APOA1 mRNA level in the NAFLD group was only about 0.32-fold as the control, YCHT in middle and high doses markedly promoted the APOA1 gene expression of NAFLD mice (Fig. 8H).